Search Results

The health fund for the International Union of Operating Engineers is suing Eli Lilly, Novo Nordisk and Sanofi, as well as CVS Health and other PBMs, for "drastically" increasing the price of life-saving meds for "illicit profits."

A settlement between the drugmaker and insulin patients that would have capped patients' out-of-pocket insulin costs at $35 for 4 years has fallen apart, after an "unfavorable ruling" from the judge overseeing the case.

In a recent speech, President Biden overstated the average monthly cost that patients were paying prior to the Inflation Reduction Act: The out-of-pocket cost for insulin was $58 for a 30-day supply, says a HHS report.

Novo Nordisk's list price for a monthly package of Ozempic is $935.77 before insurance and other rebates, yet it can be manufactured for between $0.89 to $4.73 a month, according to researchers at Yale University.

The average out-of-pocket cost for diabetes medications has increased by nearly 130% since 2018 – and those taking the newer GLP-1 drugs like Ozempic are feeling the increase the most, says a new GoodRx study.

"Finally, we beat Big Pharma," said President Joe Biden to U.S. Senator Bernie Sanders on Wednesday at a White House event to promote efforts to lower the cost of asthma inhalers and other health-care expenses.

Larry Krasner, Philadelphia's district attorney, filed a lawsuit against Eli Lilly, Novo Nordisk and other drugmakers and pharmacy benefit managers, on behalf of the 1.1 million Pennsylvanians who have diabetes, like himself.

The savings are not yet realized, says the Congressional Budget Office, which projects a 10-year cumulative savings of $161 billion from the phased-in drug negotiation, as well as a rebate for price increases above the inflation rate.